Positive Outlook for BioRestorative Therapies: Advancements in Clinical Trials and Financial Stability Drive Buy Rating

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on BioRestorative Therapies (BRTX – Research Report), with a price target of $8.00.

Michael Okunewitch has given his Buy rating due to a combination of factors related to BioRestorative Therapies’ progress and potential. The company is advancing in its Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease (CLDD), with recent efforts accelerating patient enrollment. The trial has received Fast Track designation from the FDA, indicating the potential significance of the treatment. Additionally, the data presented at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting suggests a promising efficacy profile, although it remains blinded.
Furthermore, BioRestorative Therapies has secured sufficient funding to continue operations into 2026, which provides financial stability. The company’s collaboration with Cartessa is expected to generate revenue to offset operational costs, despite the current lumpy revenue from biocosmeceuticals. The IND clearance for BRTX-100 to move into a Phase 2 study for cervical spinal pain also opens up new opportunities, potentially expanding its market reach. These factors collectively contribute to a positive outlook for the company’s stock.

According to TipRanks, Okunewitch is an analyst with an average return of -20.5% and a 33.00% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Ocugen, Lineage Therap, and BioRestorative Therapies.

In another report released on May 15, Roth MKM also maintained a Buy rating on the stock with a $18.00 price target.